Colorectal Cancer Clinical Trial
Official title:
Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
This study is for people with solid tumors cancer for which the standard chemotherapy drugs
have not worked. The purpose of this research is to evaluate the side effects of Xeloda
(also called capecitabine) in combination with a new anticancer agent called Gleevec (also
called imatinib mesylate). Xeloda is an anticancer drug, and can be taken by mouth. The
active ingredient is a well-studied cancer drug called 5-FU. Xeloda is approved by the FDA
for the treatment of colon cancer. Gleevec is approved in the US for the treatment of
patients with a leukemia called CML (increase of white blood cells) after failure of
standard therapy. It is also approved by the FDA for patients with Gastrointestinal Stromal
Tumors (a rare tumor in the digestive tract).
This study will test how much Gleevec we can safely give with Xeloda. Xeloda will be given
at the recommended dose for colorectal cancer and Gleevec will be given in increasing
amounts.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 2010 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective. - SWOG performance status 0-2. - ANC greater than 1500, platelets greater than 100,000. - Total bilirubin less than 2 x upper limit of normal, or less than 3 x upper limit of normal in patients with liver metastasis. Transaminase (AST and/or ALT) less than 2 x upper limit of normal or less than 3 x upper limit of normal in patients with liver metastasis. - Serum creatinine less than 1.25 x institutional upper limit of normal. - Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Exclusion Criteria: - Patient has received any other investigational agent- within 28 days of first day of study drug dosing. - Patient with another primary malignancy except if the other primary malignancy is neither currently clinically significant nor requiring active intervention. - Patient has another severe and/or life-threatening medical disease. - Patient has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis). - Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. - Patient has received chemotherapy within 4 weeks (6 weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry unless urgent enrollment needed and approved by Novartis. - Patient had a major surgery within 2 weeks prior to study entry. - Patients with symptomatic brain metastasis. - Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (e.g. congestive heart failure, myocardial infarction within 6 months of study) - Medical, social or psychological factors interfering with compliance. - Patients under therapeutic coumadin therapy. - Patients under routine systemic corticosteroid therapy. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | USC/Norris Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | Novartis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer. | 4 weeks | Yes | |
Secondary | To determine the time to progression, survival and response rate. | Until Patient goes off study | No | |
Secondary | To obtain preliminary data on molecular correlates to determine clinical efficacy | Until Patient Goes off study | No | |
Secondary | Toxicity. | 30 days after patient receives last drug dose | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |